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ABSTRACT
Aberrant Hedgehog (Hh)/glioma-associated oncogene (GLI) signaling has 
been implicated in cancer progression. Here, we analyzed GLI1, Sonic Hedgehog 
(Shh) and NF-κB expression in 51 breast cancer (ductal carcinoma) tissues using 
immunohistochemistry. We found a positive correlation between nuclear GLI1 
expression and tumor grade in ductal carcinoma cases. Cytoplasmic Shh staining 
significantly correlated with a lower tumor grade. Next, the in vitro effects of two 
Hh signaling pathway inhibitors on breast cancer cell lines were evaluated using the 
Smoothened (SMO) antagonist GDC-0449 and the direct GLI1 inhibitor GANT-61. 
GDC-0449 and GANT-61 exhibited the following effects: a) inhibited breast cancer 
cell survival; b) induced apoptosis; c) inhibited Hh pathway activity by decreasing 
the mRNA expression levels of GLI1 and Ptch and inhibiting the nuclear translocation 
of GLI1; d) increased/decreased EGFR and ErbB2 protein expression, reduced p21-
Ras and ERK1/ERK2 MAPK activities and inhibited AKT activation; and e) decreased 
the nuclear translocation of NF-κB. However, GANT-61 exerted these effects more 
effectively than GDC-0449. The in vivo antitumor activities of GDC-0449 and GANT-
61 were analyzed in BALB/c mice that were subcutaneously inoculated with mouse 
breast cancer (TUBO) cells. GDC-0449 and GANT-61 suppressed tumor growth of 
TUBO cells in BALB/c mice to different extents. These findings suggest that targeting 
the Hh pathway using antagonists that act downstream of SMO is a more efficient 
strategy than using antagonists that act upstream of SMO for interrupting Hh signaling 
in breast cancer.
INTRODUCTION
The Hedgehog (Hh)/glioma-associated oncogene 
(GLI) pathway is a complex signaling cascade that 
performs crucial functions in vertebrate embryogenesis 
and adult tissue homeostasis [1]. Three Hh homologs 
have been identified in vertebrates: Sonic Hedgehog (Shh), 
Indian Hedgehog (Ihh) and Desert Hedgehog (Dhh) [2, 3].
Hh ligands initiate “canonical” Hh signaling by 
binding to a 12-span transmembrane protein receptor 
termed Patched-1 (Ptch), which is located at the base of a 
non-motile structure that protrudes from the cell surface, 
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known as the “primary cilium” [3, 4]. 
In the absence of an Hh ligand, Ptch represses signal 
transduction by inhibiting the 7-span transmembrane 
protein Smoothened (SMO) from entering the cilium. 
Upon ligand binding, SMO enters the cilium and 
transduces the Hh signal, activating the cytoplasmic GLI 
family of zinc-finger transcription factors and promoting 
their translocation to the nucleus. Three GLI proteins 
are involved in vertebrate Hh signaling; GLI1 and GLI2 
stimulate but GLI3 antagonizes the function of Shh-
GLI1/2 [3, 4].
GLI activation induces the transcription of Hh 
target gene products, including ubiquitous genes such as 
GLI1, Ptch1 and Hh-interacting protein (Hhip) and cell 
type-specific genes such as Cyclin D, Myc, Bmi1, Bcl-2, 
vascular endothelial growth factor (VEGF), angiopoietins 
and SNAIL, depending on the cell type [3, 5]. In addition, 
Hh signaling down-regulates E-cadherin [3, 5].
GLI protein activation is controlled at different 
levels via phosphorylation or acetylation by inhibitors 
such as Suppressor of Fused (SuFu), REN/KCTD11/
KCASH1, protein kinase A (PKA), and glycogen synthase 
kinase 3b (GSK3b) and activators such as Dyrk1, Ras and 
AKT [6-10].
Aberrant Hh signaling, which can be achieved 
by mutational inactivation of Ptch, aberrant expression 
of its ligand, constitutive activation of SMO or gene 
amplification of GLI-associated transcription factors, 
has been implicated in the initiation and/or maintenance 
of different cancer types, including basal cell carcinoma 
(BCC), gastrointestinal, lung, and brain tumors and 
rhabdomyosarcoma [3]. In addition, dysregulation of 
Hh signaling can be involved in the development and 
progression of breast cancer [11]. Mutations in Hh pathway 
genes have been identified at a low frequency in breast 
cancer cases, although no function of these mutations in 
breast cancer has been shown [12-15]. Conversely, several 
studies reported the overexpression of an Hh ligand, often 
Shh, and the Hh transcriptional targets GLI1 and Ptch1, 
thus activating the Hh pathway, in breast cancer [11, 
16-19]. Shh expression was up-regulated in early-stage 
breast carcinoma, suggesting that the up-regulation of 
Shh may be an early event in breast carcinogenesis [19]. 
Furthermore, the positive correlation of NF-κB expression 
with Shh up-regulation suggests that NF-κB controls Shh 
expression in breast cancer [19]. Indeed, accumulating 
evidence has indicated that the Hh/GLI signaling cascade 
contributes to malignant transformation via cross-talk with 
ErbB receptors and NF-κB [4, 20, 21]. 
Targeting the Hh pathway could be a promising 
therapy for several types of tumors. More than 50 
compounds have been identified to inhibit Hh signaling 
in cancer [22]. In particular, GDC-0449 (Vismodegib/
ErivedgeTM), an SMO antagonist, has entered clinical 
trials and was approved in January 2012 by the FDA for 
the treatment of adults with locally advanced or metastatic 
BCC who cannot be treated with surgery or radiation [23, 
24]. Another promising therapeutic agent is GANT-61, 
which directly binds to the transcription factor GLI [25]. 
The efficacy of blocking the Hh pathway using GANT-61 
is under investigation in many preclinical studies [25].
In this study, we assessed the expression levels 
of GLI1, Shh and NF-κB in 51 ductal breast carcinoma 
specimens by immunohistochemical analysis and 
their correlations with clinico-pathological variables. 
Furthermore, we explored the in vitro effects of GDC-
0449 and GANT-61 on cell proliferation, cell cycle 
regulation and Hh, ErbB receptors and pro-survival 
signaling pathways in human (MDA-MB-231, MDA-
MB-453, MDA-MB-468, T47-D, MCF-7, BT-474, and 
SK-BR-3) and mouse (TUBO) breast cancer cell lines. 
In addition, we evaluated the in vivo antitumor activities 
of these two inhibitors in BALB/c mice that were 
transplanted with TUBO cells. Our results demonstrate 
the aberrant expression of Hh signaling pathway members 
in breast carcinoma and the in vitro and in vivo anti-cancer 
activities of two Hh pathway inhibitors.
RESULTS
GLI1, Shh and NF-κB expression in human breast 
carcinoma specimens
To assess the expression of GLI1, Shh and NF-κB 
in breast cancer tissues, immunohistochemical analysis 
was performed using specific antibodies. Staining for 
GLI1, Shh and NF-κB was analyzed by employing a 
tissue microarray composed of 51 ductal breast carcinoma 
specimens (G1: n = 10; G2: n = 31; and G3: n = 10). 
The expression of GLI1, Shh and NF-κB correlated with 
clinico-pathological variables including histological type, 
tumor grade, tumor size, lymph node metastasis, and 
EGFR, ErbB2, estrogen receptor (ER) and progesterone 
receptor (PR) expression (Table 1).
Nuclear expression of GLI1 was observed 
in 33/51 (65%) carcinoma samples, including 3/10 
(30%), 23/31 (74%) and 7/10 (70%) G1, G2 and G3 
tumors, respectively. The nuclear GLI1 staining was 
heterogeneous, ranging from 10% to 80% of all cells, 
with a mean percentage of 41%. The number of carcinoma 
specimens and the percentage of tumor cells displaying 
nuclear GLI1 expression were significantly associated 
with the tumor grade (Table 1). Nuclear GLI1 expression 
was observed in 26/43 (60%) ErbB2-negative tumor 
samples and 7/8 (88%) ErbB2-positive tumor samples, and 
the mean percentage of cells with nuclear GLI1 staining 
was 37 and 55%, respectively. The percentage of cells 
displaying nuclear GLI1 staining positively correlated 
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with ErbB2 positivity (p = 0.027) in the carcinoma 
samples. However, nuclear GLI1 staining did not correlate 
with the expression of the other analyzed receptors, and 
no correlation was found between GLI1 expression and 
lymph node involvement or tumor size. 
Cytoplasmic Shh expression was observed in 30/51 
(59%) carcinoma samples (4/10 (40%) of G1, 19/31 
(61%) of G2 and 7/10 (70%) of G3 samples). The mean 
percentage of cells displaying cytoplasmic Shh staining 
was 97%. The percentage cells displaying cytoplasmic 
Shh staining correlated with the tumor grade. In addition, 
we observed cytoplasmic Shh expression in 25/43 (58%) 
ErbB2-negative and 5/8 (63%) ErbB2-positive tumors, in 
13/23 (57%) PR-negative and 17/28 (61%) PR-positive 
tumors and in 8/16 (50%) ER-negative and 22/35 (63%) 
ER-positive tumors. However, no correlation between 
cytoplasmic Shh staining and expression of these receptors 
was found.
Notably, nuclear Shh staining was found in 5/51 
(10%) carcinoma samples. However, no correlation 
between nuclear Shh staining and any clinico-pathological 
variable was detected. 
NF-κB expression was observed in 20/51 (39%) 
carcinoma specimens (4/10 (40%) for G1; 15/31 (48%) 
G2; and 1/10 (10%) G3 samples). In addition, we found 
NF-κB expression in 17/43 (40%) ErbB2-negative and 
3/8 (38%) ErbB2-positive tumors; in 9/23 (39%) PR-
negative and 11/28 (39%) PR-positive tumors; and in 
5/16 (31%) ER-negative and 15/35 (43%) ER-positive 
tumors. NF-κB expression in the carcinoma specimens 
positively correlated with smaller tumor size (p = 0.034). 
Representative immunostaining results are shown in 
Figure 1.
Inhibition of breast cancer cell survival by GDC-
0449 and GANT-61
The aberrant expression of Hh signaling pathway 
members in breast carcinoma samples prompted us to 
evaluate the in vitro effects of two Hh signaling pathway 
inhibitors on breast cancer cell lines. GDC-0449 is an 
SMO antagonist, and GANT-61 directly inhibits GLI. 
The survival of human (MCF-7, T47-D, MDA-
MB-231, MDA-MB-468, MDA-MB-453, BT-474, and 
SK-BR-3) and mouse (TUBO) breast cancer cell lines 
was evaluated by the sulforhodamine B (SRB) assay after 
Figure 1: GLI1, Shh and NF-κB expression in human breast carcinoma specimens. Representative immunohistochemical 
staining of samples from 3 patients with ductal carcinoma. The immunoreactivity of the samples was visualized by immunoperoxidase 
staining using specific antibodies as described in the “Materials and methods” section. Original magnification, 200x.
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exposing the cells to increasing doses of GDC-0449 (3-
12 µM) or the vehicle control (DMSO) for 48, 72, 96 
hours or 6 days. The same assay was performed after 
exposing the cells to increasing doses of GANT-61 (1-20 
µM) or the vehicle control (DMSO) for 48 and 72 hours. 
Experiments were also performed using TUBO cells to 
establish whether this mouse cell line was susceptible 
to the in vitro antitumor activity of these inhibitors and 
would thus be suitable for transplantation into BALB/c to 
generate tumors for the purpose of determining the in vivo 
antitumor effects of these two inhibitors. 
GDC-0449 decreased cell survival in all cell lines, 
although only at the highest dose (12 µM) and after 72 
and 96 hours or 6 days of treatment. This effect was 
Figure 2: Effects of GDC-0449 (GDC) and GANT-61 (GANT) on the survival of breast cancer cells. The survival of human 
(MCF-7, T47-D, MDA-MB-231, MDA-MB-468, MDA-MB-453, BT-474, and SK-BR-3) and mouse (TUBO) breast cancer cell lines and 
of human MCF-10A mammary epithelial cells were assessed by the SRB assay after 48, 72, 96 hours or 6 days of treatment with DMSO or 
GDC-0449 (Panel A.) or after 48 and 72 hours of treatment with DMSO or GANT-61 (Panel B.). The percentage of surviving cells treated 
with a compound or the vehicle control was calculated by normalizing the O.D. value to that of the untreated control cultures. The results 
are expressed as the means±SD of three independent experiments performed in triplicate (˟p ≤ 0.05, *p ≤ 0.01, #p ≤ 0.001 compared with 
the cultures treated with DMSO).
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particularly evident in MCF-7, T47-D, SK-BR-3 and BT-
474 cells, in which GDC-0449 significantly reduced cell 
survival at 12 µM after 48 hours. In addition, GDC-0449 
reduced MCF-7 and T47-D cell survival at 6 µM and SK-
BR-3 cell survival at 6 and 3 µM after 6 days of treatment. 
The mean results of three independent experiments are 
reported in Figure 2, panel A.
The effect of GANT-61 on cell proliferation was 
dose- and time-dependent and was significant compared 
with the vehicle control at doses from 5 to 20 µM in 7 out 
of the 8 examined cell lines after 48 hours and in all cell 
lines after 72 hours of treatment. GANT-61 significantly 
reduced cell survival at all doses tested after 72 hours only 
in MDA-MB-468 cells. GANT-61 significantly decreased 
cell survival in SK-BR-3 cells (after 48 and 72 hours) and 
T47-D cells (after 72 hours) when applied at the 2.5 µM 
dose. The mean results of three independent experiments 
are reported in Figure 2, panel B.
To evaluate the non-specific toxic effects of these 
drugs, the survival of human MCF-10A mammary 
epithelial cells, which are a non-tumorigenic epithelial cell 
line derived from mammary glands, was evaluated upon 
treatment with each compound (Figure 2, panel A and B). 
Notably, GDC-0449 did not alter MCF-10A cell survival. 
In addition, GANT-61 significantly reduced MCF-10A 
cell survival only at the highest doses (20 and 15 µM), 
suggesting an in vitro toxic effect of this compound when 
applied at these high doses. No effects of GANT-61 on 
MCF-10A cells were observed at lower doses.
Overall, our results demonstrated that GANT-61 is 
more effective than GDC-0449 in reducing the survival of 
breast cancer cells. 
Figure 3: Effects of GDC-0449 (GDC) and GANT-61 (GANT) on the proportion of cells in sub-G1 phase of the cell 
cycle. FACS analysis of DNA content was performed on breast cancer cells treated for 96 hours (MDA-MB-231, MDA-MB-453, BT-474, 
TUBO) or 6 days with DMSO or GDC-0449 (Panel A) or for 48 hours with DMSO or GANT-61 (Panel B). The results are expressed as 
the means±SD of three independent experiments performed in triplicate (˟p ≤ 0.05, *p ≤ 0.01, #p ≤ 0.001 compared with the cultures treated 
with DMSO).
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Figure 4: PARP-1 cleavage, the Bax/Bcl-2 expression ratio and the p53 expression level in breast cancer cell lines 
treated with GDC-0449 (GDC) or GANT-61 (GANT). Western blotting was performed on cells that were treated with GDC-0449 
(12 μM) or DMSO for 6 days or with GANT-61 (10 μM) or DMSO for 48 hours. n.d. = not detected.
Table 1: Expression of GLI1, Shh and NF-κB in ductal breast carcinoma specimens and their 
correlation with clinico-pathological variables
Number
of Specimens
GLI1
Nuclear
Pos (%)*
Shh
NF-κB
Pos
(%)*Cytoplasmic
Pos (%)*
Nuclear
Pos (%)*
Histological Type Invasive Ductal 51 33 (41±19) 30 (97±13) 5 (86±31) 20 (100)
T Classification
T1
T2
T3
T4
18
29
1
3
11 (41±22)
19 (40±19)
1 (60)
2 (35±7)
13 (100)
15 (93±18)
0
2(100)
2 (100)
3 (77±40)
0
0
11e (100)
9e (100)
0e
0e
Grading of Invasive 
Ductal
G1
G2
G3
10
31
10
3a (15±5)b
23a (45±19)b
7a (40±14)b
4 (100)d
19 (100)d
7 (86±24)d
1 (100)
4 (83±35)
0
4 (100)
15 (100)
1 (100)
Lymph node 
involvement
Negative
Positive
25
26
18 (41±22)
15 (41±17)
12 (100)
18 (94±16)
3 (77±40)
2 (100)
8 (100)
12 (100)
EGFR Negative (0-1+)Positive (2-3+)
50
1
32 (40±19)
1 (70)
30 (97±13)
0
5 (86±31)
0
20 (100)
0
ErbB2 Negative (0-1+)Positive (2-3+)
43
8
26 (37±18)c
7 (55±18)c
25 (96±14)
5 (100)
4 (100)
1 (30)
17 (100)
3 (100)
ER NegativePositive
16
35
12 (42±19)
21 (40±20)
8 (88±23)
22 (100)
1 (100)
4 (83±35)
5 (100)
15 (100)
PR NegativePositive
23
28
16 (44±20)
17 (43±19)
13 (96±14)
17 (97±12)
1 (100)
4 (83±35)
9 (100)
11 (100)
*mean nuclear staining (%)±standard deviation. a Fisher’s exact test: G2 vs G1 p = 0.022; G2+G3 vs G1 p = 0.023; b Student’s 
T test: G2 vs G1 p = 0.017; G3 vs G1 p = 0.020; G2+G3 vs G1 p = 0.012; c Student’s T test: ErbB2 positive vs negative p = 
0.027; d Student’s T test: G2 vs G3 p = 0.014; G1+G2 vs G3 p = 0.007; e Fisher’s exact test: T1 vs T2+T3+T4 p = 0.034.
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Figure 5: The GLI1 and Ptch mRNA levels and the nuclear translocation of GLI1 after treatment with GDC-0449 
(GDC) or GANT-61 (GANT) in breast cancer cell lines. Panel A. Real-time q-PCR was performed to assess the GLI1 and Ptch 
mRNA levels in RNA that was isolated from breast cancer cell lines that had been treated with GDC-0449 (12-25 µM for 24 hours and 
50 µM for 48 hours), GANT-61 (20 µM for 48 hours) or DMSO as described in the “Materials and methods”. The GLI1 and Ptch mRNA 
expression levels were analyzed after normalization to the controls. The results are expressed as the mean values of three independent 
experiments (*p < 0.05 compared with the cultures treated with DMSO; X: the cells were dead). Panel B. Immunofluorescence analysis 
was performed on MCF-7 and SK-BR-3 breast cancer cells after treatment with GANT-61 (10 µM) or vehicle alone for 24 hours. After the 
treatment, the cells were fixed and incubated with an anti-GLI1 antibody, and after washing, the cells were labeled with an Alexa Fluor-594-
conjugated goat anti-rabbit IgG antibody. The nuclei were counterstained with Hoechst. Original magnification, 400x.
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Effect of GDC-0449 and GANT-61 on cell cycle 
distribution in breast cancer cell lines
To evaluate the effect of GDC-0449 and GANT-61 
on cell cycle distribution, FACS analysis of DNA content 
was performed on 8 breast cancer cell lines treated with 
increasing doses of GDC-0449 (3 to 25 µM) for 96 hours 
or 6 days or GANT-61 (5 to 20 µM) for 48 hours. DMSO 
was used as the vehicle.
GDC-0449 treatment at the highest dose increased 
the percentage of MDA-MB-468 and T47-D cells in the 
sub-G1 phase and exerted the same effect on MCF-7 cells 
at 25-12 µM and on SK-BR-3 cells at all doses tested 
(Figure 3, Panel A). The increase in the percentage of 
cells in sub-G1 phase was associated with a decrease in 
the percentage of cells in G0/G1 phase in MDA-MB-468, 
T47-D, and SK-BR-3 cells and with a reduction in the 
percentage of cells in S and G2/M phases in MCF-7 cells. 
The mean results of three independent experiments are 
reported in Supplementary Table 1.
Treatment with GANT-61 dose-dependently 
increased the percentage of cells in sub-G1 phase in all 
cell lines. Pooling the data from these 8 cell lines, the 
percentage of cells in sub-G1 phase ranged from 2.00 
to 8.98% in cultures treated with DMSO; from 6.31 to 
23.91% in cultures treated with 5 µM GANT-61; from 
24.28 to 84.12% in cultures treated with 10 µM GANT-61; 
and from 67.37 to 96.59% in cultures treated with 20 µM 
GANT-61 (Figure 3, Panel B). The increase in the sub-G1 
fraction was associated with dose-dependent decreases 
in the percentage of cells in G0/G1, S or G2/M phases. 
The mean results of three independent experiments are 
reported in Supplementary Table 2.
In agreement with our above results, GANT-61 
treatment appears to be more effective than GDC-0449 in 
increasing the percentage of cells in sub-G1 phase in all 
cell lines. Indeed, GANT-61 was effective after 48 hours, 
but GDC-0449 was effective only in 4 cell lines after 6 
days of treatment.
Figure 6: Effects of GDC-0449 and GANT-61 on the expression and activation of ErbB receptors and pro-survival 
signaling pathway members. Western blotting was performed on cells that were treated with GDC-0449 (12 μM) or DMSO vehicle 
for 6 days or with GANT-61 (10 μM) or DMSO vehicle for 48 hours. The levels of p-ERK1/2 were compared with the total ERK1/2 protein 
level. The level of p-AKT was compared with the AKT protein level. n.d. = not detected.
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Effects of GDC-0449 and GANT-61 on p53, Bax, 
Bcl-2 and Poly(ADP-ribose) polymerase-1 (PARP-
1)
To corroborate that the GDC-0449- and GANT-
61-induced increase in the percentage of cells in sub-G1 
phase was partially caused by the induction of apoptosis, 
PARP-1 cleavage and the Bax/Bcl-2 expression ratio were 
analyzed by Western blotting.
T47-D, MCF-7 and SK-BR-3 breast cancer cells 
were treated with 12 µM GDC-0449 or DMSO for 6 days. 
Alternatively, T47-D, MCF-7, SK-BR-3, MDA-MB-231, 
MDA-MB-468, MDA-MB-453 and BT-474 breast cancer 
cells were treated with 10 µM GANT-61 or DMSO for 48 
hours. After incubation, the cells were lysed, resolved in 
10% SDS-PAGE, transferred to nitrocellulose membranes 
and incubated with specific antibodies. The results varied 
according to the cell line examined, likely because 
different breast cancer cell lines have distinct phenotypes 
and genetic backgrounds (ER, PR, ErbB2, p53 and Ras 
expression statuses) [26-31] (Supplementary Table 3).
PARP-1, an enzyme that controls DNA repair, cell 
cycle progression and cell death, is cleaved by caspases 
during the apoptotic process. This cleavage can be 
detected by Western blotting using a specific antibody that 
recognizes both the full-length and C-terminally cleaved 
forms of PARP-1. 
In GDC-0449-treated cells, although no increase 
in PARP-1 cleavage was observed, decreased PARP-1 
expression was detected in SK-BR-3 cells (p = 0.02). In 
addition, the amount of pro-apoptotic Bax protein and 
the Bax/Bcl-2 ratio were increased following GDC-0449 
treatment compared with DMSO treatment in all cell lines. 
Bcl-2 expression was not detected in T47-D and SK-BR-3 
cells. The increased Bax/Bcl-2 expression ratio in MCF-7 
cells and the increased Bax expression level in T47-D and 
SK-BR-3 cells might shift the cellular balance toward a 
pro-apoptotic state (Figure 4 and Supplementary Table 4).
Treatment with GANT-61 induced PARP-1 cleavage 
in MCF-7, MDA-MB-468 and BT-474 cells but not in the 
Figure 7: Inhibition of the nuclear translocation of NF-κB upon GANT-61 treatment. Immunofluorescence analysis was 
performed on MCF-7 and SK-BR-3 breast cancer cells after treatment with GANT-61 (10 µM) or vehicle alone for 24 hours. After the 
treatment, the cells were fixed, incubated with an anti-NF-κB antibody, washed, and labeled with an Alexa Fluor-488-conjugated goat anti-
mouse IgG antibody. The nuclei were counterstained with Hoechst. Original magnification, 400x.
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other cell lines. However, decreased PARP-1 expression in 
MCF-7 cells was observed after treatment with GANT-61 
(p = 0.03). GANT-61 treatment increased the expression of 
the pro-apoptotic factor Bax and decreased the expression 
of Bcl-2 in MCF-7 (p = 0.03), T47-D (p < 0.001) and 
MDA-MB-453 (p = 0.006) cells. These events can shift 
the cellular balance towards a pro-apoptotic state. The 
expression of these apoptotic regulatory proteins was not 
significantly altered by GANT-61 treatment in the other 
cell lines (Figure 4 and Supplementary Table 4).
Next, to determine whether GDC-0449- or GANT-
61-induced apoptosis requires p53, the expression of p53 
was analyzed. p53 expression was significantly increased 
in GDC-0449-treated MCF-7 (p = 0.02) and T47-D (p = 
0.04) cells, but remained unchanged in SK-BR-3 cells 
(Figure 4 and Supplementary Table 4). 
GANT-61 treatment increased p53 expression in 
MCF-7 and MDA-MB-231 cells (p = 0.005 and p = 0.002, 
respectively); decreased p53 expression in T47-D (p = 
0.02), SK-BR-3 (p = 0.01) and MDA-MB-453 (p = 0.04) 
cells; and did not change p53 expression in the remaining 
cell lines (Figure 4 and Supplementary Table 4).
Effects of GDC-0449 and GANT-61 on the GLI1, 
GLI2 and Ptch mRNA levels and the nuclear 
translocation of GLI1
To evaluate the effect of treatment with GDC-0449 
or GANT-61 on the activity of the Hh pathway, real-time 
q-PCR was performed on RNA that was isolated from 
breast cancer cells treated with GDC-0449 (12-25 µM for 
24 hours and 50 µM for 48 hours), GANT-61 (20 µM for 
48 hours) or DMSO. After RNA isolation, cDNA synthesis 
was performed, and quantitative reverse transcription PCR 
(RT-PCR) analysis of the GLI1, GLI2 and Ptch mRNA 
expression levels was performed after normalization to 
the controls. The GLI1 and Ptch mRNA levels before and 
after cell treatment are reported in Figure 5, panel A.
Our results indicated that the GLI1 mRNA levels 
were greatly decreased after GDC-0449 treatment only in 
SK-BR-3 cells at 12-25 µM (p < 0.05); at 50 µM, GLI1 
mRNA was not detectable. In T47-D and TUBO cells, 
the GLI1 mRNA levels were significantly decreased (p 
< 0.05) only at the highest dose of GDC-0449 (50 µM). 
No reduction in the GLI1 mRNA levels after GDC-0449 
treatment was observed in the other cell lines. Conversely, 
GANT-61 treatment significantly decreased the GLI1 
mRNA levels (p < 0.05) in SK-BR-3, T47-D, MCF-7, 
MDA-MB-231 and TUBO cells. In MDA-MB-468 cells, 
the GLI1 mRNA levels were not detectable even when 
lower doses of GANT-61 were applied. 
The Ptch mRNA levels were slightly but 
significantly decreased after GDC-0449 treatment only 
in T47-D cells at high doses (25-50 µM). In the other 
cell lines, no reduction in the Ptch mRNA levels after 
GDC-0449 treatment was detected compared with the 
control treatment. Conversely, after GANT-61 treatment, 
a significant decrease (p < 0.05) in the Ptch mRNA 
levels in 5 of the 8 examined cell lines (T47-D, MCF-
7, MDA-MB-231, MDA-MB-453 and MDA-MB-468) 
was observed. The Ptch mRNA levels were not detectable 
in SK-BR-3 cells (Figure 5, panel A). Accordingly, our 
results suggest that GANT-61 inhibits the Hh pathway 
more potently than GDC-0449. The distinct activities of 
GANT-61 and GDC-0449 on the GLI1 and Ptch mRNA 
levels in different cell lines might be due to variations in 
the basal activity of their promoters in these cells. Some 
of these cells possess different activated Hh components. 
GLI1 activation promotes its translocation to the nucleus 
to initiate the transcription of Hh target genes. To further 
corroborate the inhibitory effects of GANT-61 on the Hh 
pathway, immunofluorescence analysis was performed 
to detect GLI1 expression in MCF-7 and SK-BR-3 cells 
that were treated with 10 µM GANT-61 or DMSO for 24 
hours. GANT-61 inhibited the translocation of GLI1 to 
the nucleus. Decreased nuclear expression of GLI1 was 
observed in MCF-7 and SK-BR-3 cells after GANT-61 
treatment compared with the control treatment (Figure 5, 
panel B). 
The GLI2 mRNA levels were very low and 
were unchanged in most the cell lines upon treatment 
with GDC-0449 or GANT-61. In addition, GLI2-
overexpressing cell lines, except MDA-MB-231 and SK-
BR-3, did not show a significant change in GLI2 mRNA 
levels following treatment. MDA-MB-231 and SK-
BR-3 cells exhibited a significant reduction in the GLI2 
mRNA levels only at the lowest dose of GDC-0449, thus 
indicating the presence of a compensatory mechanism that 
induces GLI2 transcription following strong inhibition of 
GLI target gene products (Supplementary Figure 1). 
Effects of GDC-0449 and GANT-61 on the 
expression and activation of ErbB receptors and 
pro-survival signaling pathway members
ErbB receptors are members of one of the primary 
signal transduction pathways implicated in cancer cell 
growth [32]. In addition, accumulating evidence has 
indicated that cross-talk between ErbB receptors and 
the Hh/GLI signaling pathway is involved in neoplastic 
transformation [20]. 
To evaluate whether GDC-0449 or GANT-61 alters 
EGFR/ErbB2 expression and ERK1/2 expression and 
activation, Western blotting analysis was performed after 
treating cells with GDC-0449 (12 µM) or DMSO for 6 
days or with GANT-61 (10 µM) or DMSO for 48 h. The 
results varied according to the cell line used.
GDC-0449 reduced EGFR expression in T47-D cells 
(p = 0.03) but did not change EGFR expression in MCF-
7 and SK-BR-3 cells. GDC-0449 had no notable effect 
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on the ErbB2 protein levels (Figure 6 and Supplementary 
Table 4). 
In addition, GANT-61 slightly reduced EGFR 
expression in T47-D (p = 0.02), SK-BR-3 (p = 0.04) 
and MDA-MB-231 (p = 0.01) cells but increased EGFR 
expression in MCF-7 (p = 0.02), BT-474 (p = 0.004) and 
MDA-MB-468 (p = 0.006) cells. EGFR expression was 
not detectable after GANT-61 treatment in MDA-MB-453 
cells, and this result suggested that this treatment reduced 
EGFR expression. GANT-61 decreased ErbB2 expression 
in T47-D (p = 0.008) and MDA-MB-453 (p = 0.005) cells 
but did not change its expression in MCF-7, SK-BR-3 and 
BT-474 cells; ErbB2 expression was not detectable in the 
other cell lines (Figure 6 and Supplementary Table 4). 
We also investigated the effect of GDC-0449 or 
GANT-61 on the expression and phosphorylation of 
ERK1/ERK2 (ERK1/2), which are activated by ErbB 
receptors. The levels of phosphorylated ERK1 and ERK2 
proteins were compared with the total ERK protein level. 
GDC-0449 did not alter the basal or phosphorylated 
ERK (p-ERK)1/2 protein expression levels in T47-D and 
SK-BR-3 cells, but GDC-0449 reduced the p-ERK1/2 
levels in MCF-7 cells (p = 0.007 for p-ERK1; p = 0.03 
for p-ERK2) (Figure 6 and Supplementary Table 4). The 
total ERK1/2 levels remained the same after GANT-61 
treatment in all cell lines. GANT-61 significantly inhibited 
ERK1/2 phosphorylation in MDA-MB-231 (p = 0.049 for 
p-ERK1; p = 0.002 for p-ERK2), MDA-MB-468 (p = 0.04 
for p-ERK1; p = 0.003 for p-ERK2) and MDA-MB-453 (p 
= 0.04 for p-ERK1; p = 0.009 for p-ERK2) cells (Figure 6 
and Supplementary Table 4).
Ras is also activated by ErbB receptors [33]. Thus, 
we analyzed the effect of GANT-61 on Ras expression in 
breast cancer cell lines using an antibody that detects an 
epitope that is common to both activated and deactivated 
H-, K- and N-Ras p21. GANT-61 significantly inhibited 
p21-Ras expression in T47-D (p = 0.026), MCF-7 (p = 
0.008), MDA-MB-231 (p = 0.006), BT-474 (p = 0.017), 
and MDA-MB-453 (p = 0.002) cells. 
Furthermore, we evaluated whether GANT-61 
treatment inhibits the protein expression of the pro-survival 
kinase AKT, which promotes tumor growth. GANT-61 
significantly decreased the activated phosphorylated 
AKT (p-AKT) protein levels compared with the control 
in MDA-MB-231 (p = 0.004), MDA-MB-468 (p = 0.03) 
and BT-474 (p = 0.03) cells. p-AKT expression was not 
detectable in MCF-7 or MDA-MB-453 cells. GANT-61 
treatment significantly increased the p-AKT/AKT ratio in 
SK-BR-3 cells compared with the control treatment (p = 
0.02) (Figure 6 and Supplementary Table 4).
Figure 8: Effect of GANT-61 (GANT) on the protein expression of ErbB2/neu, EGFR, ERK1/2 and AKT in TUBO cells, 
and treatment with GDC-0449 (GDC) or GANT suppressed tumor growth in BALB/c mice that were subcutaneously 
inoculated with TUBO cells. Western blotting was performed on murine mammary cancer (TUBO) cells that were treated with GANT-
61 (10 µM) or DMSO vehicle for 48 hours. n.d. = not determined. Panel A. Effect of GANT-61 on neu, EGFR and ERK1/2 expression. The 
levels of p-ERK1/2 were compared with the total ERK1/2 protein levels. Panel B. Effect of GANT-61 on the AKT protein level. Panel C. 
Differences in mean tumor volumes between BALB/c mice treated with GDC-0449 (GDC), GANT-61 (GANT) or corn oil:ethanol (CTRL). 
Panel D: Differences in the mean survival duration of BALB/c mice treated with GDC-0449 (GDC), GANT-61 (GANT) or corn oil:ethanol 
(CTRL). The numbers of inoculated mice are reported in the “Materials and methods”.
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Effects of GANT-61 on the nuclear translocation 
of NF-κB
Several studies suggest an interplay between 
the Hh and NF-κB signaling pathways in cancer cells. 
NF-κB activation induces its translocation from the 
cytoplasm to the nucleus. To evaluate whether GANT-61 
treatment interferes with NF-κB nuclear translocation, 
immunofluorescence analysis was performed using 
MCF-7 and SK-BR-3 cells treated with 10 µM GANT-
61 or DMSO for 24 h. GANT-61 treatment reduced the 
translocation of NF-κB to the nucleus of MCF-7 and SK-
BR-3 cells compared to the control treatment (Figure 7).
Effect of GANT-61 on ErbB2/neu and the pro-
survival signaling protein AKT in murine TUBO 
cells
To evaluate the effect of GANT-61 on ErbB2/
neu and on the AKT protein in BALB-neuT mammary 
cancer cells (TUBO) overexpressing activated rat ErbB2/
neu, the cells were treated with 10 µM GANT-61 for 48 
h, followed by Western blotting analysis. Although an 
increase in EGFR expression was observed in GANT-
61-treated cells relative to the control-treated cells (p = 
0.04), GANT-61 actually decreased the p-ERK1-2/ERK 
ratio. Indeed, after GANT-61 treatment, ERK1 and ERK2 
activation was abolished. However, no effect of GANT-61 
on neu expression was observed (Figure 8, panel A). In 
addition, GANT-61 treatment decreased the p-AKT/AKT 
expression ratio compared with the control treatment (p = 
0.01) (Figure 8, panel B). 
Thus, our results suggest that GANT-61 exerts 
antitumor effects on TUBO cells by inhibiting the MAPK 
and AKT pathways. 
GDC-0449 and GANT-61 reduced tumor growth 
in BALB/c mice subcutaneously inoculated with 
TUBO cells
To evaluate the in vivo antitumor effects of GDC-
0449 and GANT-61, groups of BALB/c female mice (5 
mice per group) were subcutaneously inoculated with 
1x106 TUBO cells in the right flank. These mice were 
simultaneously treated per os with GDC-0449 or GANT-
61 dissolved in corn oil:ethanol (4:1) or with the vehicle 
alone. 
After 3 weeks of treatment, the mice treated with 
GDC-0449 or GANT-61 showed a significant decrease in 
the mean tumor volume compared with the control mice 
(513 compared with 1070 mm3, p = 0.0084 for GDC-0449; 
142 compared with 1070 mm3, p = 0.0049 for GANT-61) 
(Figure 8, panel C). GDC-0449 increased the survival of 
BALB/c mice by one week compared with the control 
mice (p = 0.0009). After 4 weeks of treatment, the control 
mice were sacrificed because of the excessive size of their 
tumors. The GDC-0449-treated mice were sacrificed after 
5 weeks of treatment (Figure 8, panel D). Conversely, 
GANT-61 administration counteracted TUBO cell growth 
in BALB/c mice. The mean tumor volume in GANT-61-
treated mice was 238 mm3 two weeks after injection. In 
fact, 1 and 2 mice became tumor-free after 4 and 5 weeks 
of treatment, respectively (Figure 8, panel C). Overall, 
complete tumor regression was observed in 4/5 GANT-
61-treated mice after 6 weeks of treatment (p = 0.0005 for 
GANT-61 compared with vehicle; p = 0.023 for GANT-61 
compared with GDC-0449). These mice remained tumor-
free for up to 30 weeks. Only 1 GANT-61-treated mouse 
died at 5 weeks after injection, although its tumor volume 
was small (500 mm3) (Figure 8, panel D).
Overall, our results indicated specific interference 
with TUBO tumor cell growth by Hh inhibitors, and the 
effect varied according to the compound. Regarding the 
survival of BALB/c mice upon treatment, the risk of 
TUBO tumor cell growth in the corn oil-treated group was 
0.016 and 49.40 relative to the GDC-0449- and GANT-61-
treated groups, respectively. In addition, the risk of TUBO 
tumor cell growth in the GDC-0449-treated group was 
17.81 relative to the GANT-61-treated group (Table 2). 
DISCUSSION
Aberrant Hh signaling has been implicated in the 
initiation and/or maintenance of different cancer types, 
including breast cancer [34]. Hh-induced carcinogenesis 
via constitutive Hh signaling activation is caused either 
Table 2: Analysis of the survival of Balb/c mice after treatment with Hh inhibitors by the log-rank test (Mantel-Cox)
Variable Contrast Hazard ratio
95% hazard ratio 
confidence limits p value
lower upper
Treatment
GDC-0449 vs CTRL 0.016 0.001 0.19 0.0009
GANT-61 vs CTRL 49.40 5.44 449 0.0005
GANT-61 vs GDC-0449 17.81 1.47 216 0.0237
Mice were treated with GDC-0449 (GDC), GANT-61 (GANT) or corn oil:ethanol (CTRL).
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by the mutation of Hh pathway components (ligand-
independent) or by Hh overexpression (ligand-dependent). 
Mutations of Hh pathway genes have been identified at 
a low frequency in breast cancer, and no function of 
these mutations in breast cancer has been shown [12-15]. 
Alternatively, several studies reported overexpression 
of Hh ligands, often Shh, and of the Hh transcriptional 
targets GLI1 and Ptch1 and, thus, the activation of the Hh 
pathway in breast cancer [11, 16, 17].
Accordingly, we assessed the expression of Hh 
pathway members (GLI1, Shh and NF-κB) in 51 ductal 
breast carcinoma specimens by immunohistochemical 
analysis, and we correlated their expression with clinico-
pathological variables. The number of carcinoma 
specimens and the percentage of tumor cells displaying 
nuclear GLI1 expression were significantly associated 
with the tumor grade. Additionally, the percentage of 
cytoplasmic Shh staining correlated with the tumor grade. 
These results are consistent with those of other studies 
that evaluated the clinico-pathological significance 
of Hh signaling in breast tumors. Cui et al. suggested 
that Shh up-regulation may be an early event in breast 
carcinogenesis because Shh expression was elevated in 
early-stage breast carcinoma [19]. In addition, increases 
in Hh ligand expression and Hh pathway activation have 
been reported over the progression of malignant breast 
epithelial lesions from non-neoplastic masses to ductal 
carcinoma in situ (DCIS) to invasive ductal carcinoma 
(IDC) [17, 35]. Furthermore, we evaluated the cytoplasmic 
expression of NF-κB and found a positive correlation 
between the number of NF-κB-positive carcinoma 
specimens and smaller tumor size. Nakashima et al. 
reported that NF-κB can directly induce Shh expression 
in vitro and in vivo and can promote pancreatic cancer 
cell proliferation and apoptosis resistance via the Shh 
pathway [21, 36]. Interestingly, the percentage of cells 
displaying nuclear GLI1 staining positively correlated 
with ErbB2 expression in carcinoma samples (p = 0.027), 
and this result suggests the involvement of Hh pathway 
activation in the development of ErbB2-positive breast 
cancer. Thus, the Hh signaling pathway may be a potential 
therapeutic target for these types of breast cancer. In 
fact, Hh signaling can be blocked at many levels using a 
variety of small molecules that target different members 
of this pathway. More than 50 compounds have been 
identified as inhibitors of Hh signaling in cancer [22]. 
In particular, GDC-0449 (Vismodegib/ErivedgeTM), an 
SMO antagonist, entered clinical trials and was approved 
in January 2012 by the FDA for the treatment of adults 
with locally advanced or metastatic BCC who cannot be 
treated with surgery or radiation [37]. Another promising 
therapeutic agent is GANT-61, which directly inhibits the 
transcription factor GLI, and the efficacy of GANT-61 in 
blocking the Hh pathway is under investigation in many 
preclinical studies [38-40].
In light of these findings, we evaluated the in vitro 
anti-cancer activities of GDC-0449 and GANT-61 in 
human breast cancer cell lines and murine TUBO cells. 
GANT-61 was more effective than GDC-0449 in reducing 
the survival of breast cancer cells. In particular, GANT-61 
at doses ranging from 5 to 20 µM significantly reduced 
the survival of 7/8 tested cell lines after 48 hours and in all 
cell lines after 72 hours of treatment relative to the vehicle 
control. GDC-0449 significantly decreased cell survival 
in all cell lines only at the highest dose (12 µM) after 72 
hours, 96 hours or 6 days of treatment. In addition, GANT-
61 treatment induced apoptosis and altered the cell cycle 
distribution more effectively than GDC-0449. Specifically, 
GANT-61 increased the percentage of cells in sub-G1 
phase, in all breast cancer cell lines investigated after 48 
hours, whereas GDC-0449 exhibited this effect only in 4 
cell lines after 6 days of treatment.
The activation of apoptosis by GDC-0449 and 
GANT-61 was confirmed by PARP-1 cleavage or down-
regulation and/or an increase in the ratio of the pro-
apoptotic protein Bax to the anti-apoptotic protein Bcl-2. 
In addition, GANT-61 inhibited Hh pathway activity 
more potently than GDC-0449, as demonstrated by the 
decreased mRNA levels of GLI1 and Ptch after treatment 
with these compounds. Hh pathway activation leads to 
the transcription of Hh target gene products, including 
ubiquitous genes such as GLI1 and Ptch1 and cell-specific 
genes [3]. Furthermore, based on immunofluorescence 
analysis, GANT-61 inhibited the translocation of GLI1 
to the nucleus and thereby blocked the activation of GLI 
target genes. After GANT-61 treatment, nuclear GLI1 
expression was reduced in MCF-7 and SK-BR-3 cells.
These findings suggest the importance of targeting 
the Hh pathway using antagonists that act downstream of 
SMO [41]. This is a more efficient strategy for interrupting 
Hh signaling considering the presence of SMO mutations 
and of the “non-canonical” mechanism of GLI protein 
activation in cancer. Recent studies have shown that 
mutant forms of SMO are resistant to SMO antagonists 
such as GDC-0449 [42-44]. Other studies reported that 
GANT-61 inhibits GLI1/GLI2 in colon cancer cells that 
are resistant to the SMO inhibitors cyclopamine and GDC-
0449; this observation suggests SMO-independent Hh 
signaling pathway activation in colon cancer [38].
Thus, the “non-canonical” activation of the Hh 
signaling pathway in cancer leads to the transcription 
of GLI target genes in a SMO-independent manner via 
alternative signaling pathways. All “non-canonical” 
activation mechanisms described herein act together 
with the Hh pathway downstream of SMO. For example, 
the Ras and TGF-β pathways induce GLI gene activity 
in a ligand-independent manner [45]. Furthermore, 
accumulating evidence indicate that a complex interplay 
can occur between the ErbB receptor, Hh and NF-κB 
pathways. Therefore, we also investigated the effects of 
GDC-0449 and GANT-61 on the ErbB receptor and NF-
κB signaling pathways in breast cancer cell lines. The 
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responses of the cells to GDC-0449 or GANT-61 treatment 
varied according to the cell line. Indeed, breast cancer 
cell lines display different receptor (ER, PR, ErbB2) 
expression profiles and different levels of normal and 
mutated signaling proteins (p53, Ras) [26-31]. Intra-tumor 
and inter-tumor heterogeneity are features of neoplasia. 
Established human cell lines are derived from human 
breast cancer tissues or pleural effusions. Thus, breast 
cancer cell lines display the same genomic alterations 
as cancer tissues. The responses of such cells lines 
therefore might predict the resistance of cancer tissues 
to treatment. Drug resistance might involve a single or 
multiple signaling pathway alterations [46]. However, no 
correlation between the drug response and the alteration of 
any specific signaling pathway was detected. For example, 
GANT-61 induced PARP-1 cleavage in both MCF-7 and 
MDA-MB-468 cells, which express wild type and mutated 
p53, respectively. Activation of the extrinsic or intrinsic 
apoptotic signaling pathways could be responsible for the 
observed responses.
GANT-61 altered the protein expression of EGFR 
and ErbB2. In contrast, GDC-0449 had no effect on the 
ErbB2 protein level and induced a slight decrease in the 
EGFR expression level only in T47-D cells. Interestingly, 
overexpressing neu TUBO cells increased EGFR 
expression, and the neu expression level did not change 
after GANT-61 treatment. A similar result was observed 
in MDA-MB-468, MCF-7 and BT-474 cells, in which 
GANT-61 treatment increased the EGFR protein level 
but had no effect on ErbB2 expression. In these cells, 
we also observed the induction of apoptosis. Rush et al. 
recently reported that EGFR might trigger apoptosis to 
prevent prolonged EGFR signaling, which might result 
from EGFR overexpression or defective EGFR signaling 
attenuation [47]. 
In addition, GANT-61 significantly inhibited p21-
Ras expression; further studies are needed to elucidate 
the mechanism by which GANT-61 exerts this effect. 
MAPKs are the intracellular effectors of ErbB receptors 
(EGFR, ErbB2, ErbB3 and ErbB4), and hyperactivation 
of the ERK1/2 MAPK signaling pathway frequently 
occurs in human cancer and is associated with increased 
cell survival and proliferation [48]. Here, we demonstrate 
that MAPK activity was down-regulated by GANT-61 
in breast cancer cells. In particular, GANT-61 treatment 
inhibited ERK1/2 activation in ER- and PR-negative 
breast cancer cells (MDA-MB-231, MDA-MB-468 and 
MDA-MB-453 cells) and completely abolished ERK1/2 
activation in TUBO cells, leading to the overexpression of 
ErbB2/neu. In contrast, GDC-0449 reduced the p-ERK1/2 
levels only in MCF-7 cells. GANT-61 also inhibited the 
phosphorylation and activation of the pro-survival kinase 
AKT, which induces tumor growth. Indeed, AKT promotes 
cell survival and apoptosis resistance by sequestering 
various protein targets, including the FOXO family of 
forkhead transcription factors and the pro-apoptotic protein 
Bad, and by activating the pro-survival transcription factor 
NF-κB [49]. However, GANT-61 inhibited NF-κB activity 
by blocking the nuclear translocation of NF-κB in MCF-7 
and SK-BR-3 cells. 
Overall, our results suggest that both GDC-0449 and 
GANT-61 control Hh/ErbB/NF-κB signaling pathways in 
vitro, although the GLI1 inhibitor was more effective than 
the SMO inhibitor. Several studies and phase I clinical 
trials have shown that GDC-0449 has a good human safety 
profile, low plasma clearance, good oral bioavailability 
(13-53%), metabolic stability in hepatocytes, good 
absorption and wide distribution to tissues [50-52]. GDC-
0449 was administered at a dose of 150 mg daily, and its 
maximum plasma concentrations were approximately 
3.58 µM and 23 µM for single and repeated doses, 
respectively [50-53]. Accordingly, the GDC-0449 doses 
that we employed in our in vitro experiments (3-25 µM) 
are in agreement with its plasma concentrations in treated 
patients.
In addition, GDC-0449 has been effective in 
the treatment of solid organ tumors such as BCC and 
medulloblastoma [53, 54]. With respect to its efficacy in 
mouse models, GDC-0449 (12.5 mg/kg) has been shown 
to induce complete tumor regression in an allograft mouse 
model of medulloblastoma that is entirely dependent on 
the Hh pathway for growth [23]. GDC-0449 significantly 
reduced liver fibrosis and the tumor burden in aged Mdr2-
deficient mice that already exhibited advanced liver 
fibrosis and hepatocellular carcinoma [55] and blocked the 
growth of tamoxifen-resistant breast cancer cell xenografts 
in mice [56].
Concerning GANT-61, a recent study reported 
the in vivo antitumor potential of this Hh inhibitor in 
neuroblastoma. Mice subcutaneously injected into the 
flank with neuroblastoma cells were treated orally through 
gastric feeding with GANT-61 (50 mg/kg), and a reduction 
of 63% in tumor volume was observed in comparison with 
the control treatment [57].
Given these observations, we evaluated the in vivo 
therapeutic potential of these two Hh inhibitors in BALB/c 
mice that were subcutaneously inoculated into the right 
flank with TUBO cells and simultaneously treated per os 
with 2 mg of GDC-0449, GANT-61 or vehicle alone per 
mouse. Overall, our results indicated that the Hh inhibitors 
specifically interfered with TUBO tumor cell growth to 
varying extents. Indeed, considering the survival of 
BALB/c mice, the risk of TUBO tumor cell growth in the 
corn oil-treated group was 0.016 and 49.40 relative to the 
GDC-0449 and GANT-61-treated groups, respectively. In 
addition, the risk of TUBO tumor cell growth in the GDC-
0449-treated group was 17.81 relative to the GANT-61-
treated group. Mice treated with GDC-0449 or GANT-61 
showed a significant decrease in the mean tumor volume 
compared with control mice (48% decrease for GDC-0449, 
75% decrease for GANT-61) after 3 weeks of treatment. 
GDC-0449 increased the survival of BALB/c mice by only 
Oncotarget9264www.impactjournals.com/oncotarget
one week compared with the control mice (p = 0.0009). 
In contrast, TUBO cell growth was counteracted in mice 
treated with GANT-61; in 4/5 mice treated with GANT-61, 
we observed complete tumor regression after 6 weeks of 
treatment.
Our results provide evidence that GDC-0449 and 
GANT-61 suppress the growth of human and mouse breast 
cancer cells in vitro and in vivo, although to different 
extents. However, the GLI1 inhibitor blocked the Hh 
pathway more effectively than the SMO inhibitor, likely 
because cancer cells exhibit “non-canonical” activation of 
the Hh pathway, which is caused by alternative signaling 
pathways (ErbB receptors, NF-κB, Wnt, and Notch) [58]. 
To date, SMO inhibitors have mainly been employed to 
target Hh signaling. However, resistance to the presently 
employed SMO inhibitors has been found in BCC patients. 
Thus, drugs directly inhibiting GLI transcription factors 
will also be helpful in the treatment of tumors harboring 
mutations in SMO or in factors downstream of SMO (e.g., 
SuFu) [41].
Overall, GANT61 inhibits cell growth, DNA 
damage repair, epithelial-mesenchymal transition, cancer 
stem cell survival and induces apoptosis, autophagy and 
inflammatory responses [41]. Accordingly, it is important 
to develop new breast cancer therapies based on the 
combination of Hh pathway inhibitors and ErbB2, EGFR, 
Wnt and Notch signaling inhibitors. 
MATERIALS AND METHODS
Reagents
DMSO, GANT-61, Sulforhodamine B (SRB) and 
Hoechst 33342 were purchased from Sigma Aldrich 
(Milano, Italy). GDC-0449 (CUR-0199691) was 
provided by Genentech (San Francisco, CA). Antibodies 
against AKT, and phospho-AKT were obtained from Cell 
Signaling Technology (MA, USA). Antibodies against Bax 
and Bcl-2 were from BD Pharmigen (BD Biosciences, 
San Josè, CA, USA). Antibodies against GLI1 (H-300), 
Shh (H-160), ERK1/2 (C-14), phospho-ERK (E-4), NF-
κB (p65), PARP-1, p53 (DO-1) and H-Ras (259) were 
obtained from Santa Cruz Biotechnology (CA, USA). 
Anti-ErbB2 and anti-EGFR antisera were provided by 
Dr. M.H. Kraus (University of Alabama, Birmingham, 
USA). Goat anti-rabbit IgG Alexa fluor-594-conjugated 
and goat anti-mouse IgG Alexa fluor-488-conjugated 
secondary antibody came from Invitrogen (Milano, Italy). 
A rabbit polyclonal antibody against actin and goat anti-
mouse or anti-rabbit IgG peroxidase-conjugated secondary 
antibodies were from Sigma-Aldrich. 
Tissue micro-array (TMA) and 
immunohistochemistry
The expression of different proteins in human 
tissues was determined by immunoperoxidase staining 
after incubation with specific antibodies.
We analyzed 51 invasive ductal breast carcinoma 
specimens including the following: G1 = n.10, G2 = n.31, 
and G3 = n.10. Patient tissue was obtained according to 
the ethical guidelines of the Policlinico of Tor Vergata, 
Rome. 
For TMA construction, we used tissue fragments 
left over from sampling procedures that were employed 
for diagnostic purposes. Areas of interest from breast 
carcinoma specimens were identified on corresponding 
H&E-stained sections and marked on the donor paraffin 
block. A 3-mm-thick core of the donor block was placed 
in the recipient master block of a Galileo TMA CK2500 
(Brugherio, Milano, Italy). Three cores from different 
areas of the same tissue block were arrayed for each case 
(the total amount of neoplastic cells was not less than 
1500) [59]. For immunohistochemistry, 4-µm paraffin 
sections from TMA were deparaffinized, rehydrated and 
quenched in a 0.2% hydrogen peroxide solution diluted 
in methanol. Nonspecific sites were blocked for 5 min 
in a buffer containing 100 mM Tris, BSA 2% horse 
serum, and 0.02% sodium azide. After pretreatment for 
30 min at 100°C in EDTA citric buffer, the sections were 
immunolabeled for 1 hour at room temperature with the 
primary antibodies anti-ER (prediluted; rabbit monoclonal 
antibody SP1; Ventana, Tucson, AZ USA), anti-PR 
(prediluted; rabbit monoclonal antibody 1E2; Ventana, 
Tucson, AZ USA), anti-Her2/neu (prediluted; rabbit 
monoclonal antibody 4B5; Ventana, Tucson, AZ USA), 
anti-EGFR (prediluted; rabbit monoclonal antibody 5B7; 
Ventana, Tucson, AZ USA), anti-NF-κB (1:100 diluted; 
mouse polyclonal antibody; Santa Cruz Biotechnology, 
CA, USA), anti-GLI1 (1:100 diluted; rabbit polyclonal 
antibody; Santa Cruz Biotechnology, CA, USA) and anti-
Shh (1:200 diluted; rabbit polyclonal antibody; Santa 
Cruz Biotechnology, CA, USA). This step was followed 
by a 15 min incubation with biotinylated anti-rabbit/mouse 
IgG (prediluted; Dako Denmark, Glostrup Denmark) and 
by a 15-min incubation with avidin-peroxidase complex 
(prediluted; Dako Denmark, Glostrup Denmark). The 
reactions were revealed with a Universal DAB Detection 
Kit (Dako Denmark, Glostrup Denmark) [60].
The semiquantitative expression of GLI1, Shh, 
and NF-κB in the carcinoma specimens was estimated 
at x200 magnification in at least 10 fields by two 
investigators in a blind fashion. A previously described 
score system with minor modifications was used. The 
staining intensity was semi-quantitatively classified as 
negative (-), weakly positive (+), and overexpressed (2+ 
and 3+). The percentage of cells with positive staining 
was assessed independently. A tumor was considered 
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negative for ER and PR expression if < 5% of tumor 
cell nuclei were stained. The HER2 expression level was 
scored on the basis of membrane staining intensity as 
follows: 0 (negative) and 1 + (discontinuous and weak) 
staining were considered negative, 2 + (continuous and 
weak to moderate) staining was considered borderline, 
and 3 + (continuous and strong) was considered positive. 
Borderline cases have been solved by FISH analysis. 
Accordingly, the presence of less than two copies of the 
HER2 gene was scored as negative, and that of two or 
more copies was scored as positive. Nuclear grading was 
assessed by evaluating the nuclear size, monomorphism 
or pleomorphism, the dispersion of chromatin, and the 
number of nucleoli and mitosis, and they were scored as 
low (G1), intermediate (G2) and high (G3) [61]. 
Cell lines and treatments
BALB-neuT mammary cancer cells (H-2d) (TUBO) 
that overexpress activated rat ErbB2/neu were kindly 
provided by Prof. G. Forni (University of Torino, Italy) 
[62]. Human (MDA-MB-231, MDA-MB-453, MDA-
MB-468, T47-D, MCF-7, BT-474, and SK-BR-3) and 
mouse breast cancer cell lines (TUBO) and human MCF-
10A mammary epithelial cells were maintained in DMEM 
(Dulbecco’s modified Eagle’s medium) containing 10% 
fetal bovine serum, 100 U/ml penicillin and 100 µg/ml 
streptomycin (complete medium). The cells were grown 
at 37°C in a humidified incubator with an atmosphere of 
5% CO2.
GDC-0449 and GANT-61 were dissolved in DMSO. 
For the treatments, the cells were incubated for the 
indicated times in the presence of GDC-0449 (dose range: 
3-25 µM), GANT-61 (dose range: 1-20 µM) or a vehicle 
control (DMSO ≤ 0.1%). 
Sulforhodamine B (SRB) assay
Cells were seeded at 5x103/well in 96-well plates 
and incubated at 37°C to allow cell attachment. After 24 
hours, the medium was changed and the cells were treated 
with GDC-0449 or DMSO and incubated for 48 hours, 
72 hours, 96 hours or 6 days at concentrations of 3-6-12 
µM, or with GANT-61 or DMSO and then incubated for 
48 and 72 hours at concentrations of 1-2.5-5-10-20 µM. 
The cells were then fixed with cold trichloroacetic acid 
(final concentration 10%) for 1 h at 4°C. After 4 washes 
with distilled water, the plates were air-dried and stained 
for 30 min with 0.4% (wt/vol) SRB in 1% acetic acid. 
After 4 washes with 1% acetic acid to remove the unbound 
dye, the plates were air-dried, and cell-bound SRB was 
dissolved with 200 µl/well of 10 mM unbuffered Tris base 
solution. The optical density (O.D.) of the samples was 
determined at 540 nm with a spectrophotometric plate 
reader. The percentage survival of the cultures treated with 
GDC-0449 or GANT-61 was calculated by normalizing 
their O.D. values to those of control cultures treated with 
DMSO [63]. The experiments were performed in triplicate 
and repeated three times. 
FACS analysis
Asynchronized, log-phase growing cells (60% 
confluent, approximately 2.5 x 105/well in 6-well plates) 
were treated with GDC-0449, GANT-61 or DMSO in 
complete culture medium. After 96 hours or 6 days for 
GDC-0449 (3-6-12-25 µM) or 48 hours for GANT-61 
(5-10-20 µM), adherent as well as suspended cells were 
harvested, centrifuged at 1500 rpm for 10 min and washed 
twice with cold phosphate-buffered saline (PBS). The cell 
pellets were resuspended in 70% ethanol and incubated for 
1 hour at -20°C. The cells were then washed twice with 
cold PBS, centrifuged at 1500 rpm for 10 min, incubated 
for 1 hour in the dark with propidium iodide (25 μg/ml 
final concentration in 0.1% citrate and 0.1% Triton X-100) 
and analyzed by flow cytometry using a FACSCalibur 
cytometer with CellQuest software [49].
RNA isolation and real-time q-PCR
Cells were seeded at 2 x 105 cells/well in 6-well 
plates and incubated at 37°C to allow cell attachment. 
After 24 hours, the cells were treated with GDC-0449 (50 
µM for 48 h; 12-25 µM for 24 h), GANT-61 (20 µM for 48 
h) or DMSO. After incubation, the cells were harvested, 
washed twice with PBS and centrifuged at 1200 rpm for 
10 min. 
The total RNA from the cells was extracted using 
TRI Reagent Solution (AmbionTM, Life Technologies, 
Italy), according to the manufacturer’s instructions, and 
cDNA synthesis was performed with a SuperScript II First-
Strand Synthesis kit (Invitrogen, Life Technologies, Italy). 
A quantitative real-time PCR analysis of hGLI1, hGLI2, 
hIkbα, hPtch1, mGLI1, mGLI2, mPtch1, mIkbα, hHPRT, 
hB2M, hTBP, mHPRT, mB2M, and mTBP messenger 
RNA (mRNA) was performed on cDNA using TaqMan 
gene expression assays according to the manufacturer’s 
instructions (Applied Biosystems, Life Technologies, 
Italy) and an ABI Prism 7900HT (Applied Biosystems, 
Life Technologies, Italy) as previously described [64]. 
Each amplification reaction was performed in triplicate, 
and the average of the three threshold cycles was used to 
calculate the amount of transcripts in the sample (SDS 
software; ABI). mRNA quantification was expressed, in 
arbitrary units, as the ratio of the sample quantity to the 
calibrator or to the mean values of the control samples. 
All values were normalized to three endogenous controls, 
namely HPRT, B2M, and TBP.
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Preparation of cell lysates and Western blotting
Approximately 1 x 106 cells were seeded in 100-
mm tissue culture dishes 24 hours prior to the addition of 
12 μM GDC-0449, 10 μM GANT-61 or vehicle control. 
After 48 hours (for GANT-61) or 6 days (for GDC-0449) 
of incubation, the cells were harvested, washed twice with 
cold PBS and lysed in RIPA lysis buffer (Triton X-100 
1%, SDS 0.1%, NaCl 200 mM, Tris HCl 50 mM pH 7.5, 
PMSF 1 mM, and NaOV 1 mM). After 30 min at 4°C, 
the mixtures were centrifuged at 12000 g for 15 min 
and the supernatants were analyzed by Western blotting. 
For immunoblotting analysis, 50 μg of cell lysates were 
resolved in 10% SDS-PAGE and then transferred to 
nitrocellulose membranes. After blocking, the membranes 
were incubated with specific primary antibodies at 1-2 
μg/ml concentrations overnight at 4°C. After being 
washed, the filters were incubated with goat anti-mouse 
or anti-rabbit IgG, peroxidase-conjugated antibodies and 
developed by chemiluminescence as previously described 
[65]. A densitometric analysis of autoradiographic bands 
was performed with Image J software (National Institutes 
of Health, USA) after blot scanning.
Immunofluorescence
Cells were seeded at 4 x 104 cells/well in 8-well 
chamber slides and, after 24 hours, they were treated with 
10 μM GANT, or with vehicle control. After 24 hours, the 
cells were fixed in 4% formaldehyde for 10 min, washed 
and fixed in methanol for 5 min at -20°C, then washed 
and incubated with GLI1 polyclonal antibody overnight 
at 4°C or with NF-κB monoclonal antibody for 1 hour at 
room temperature. After additional washings, the cells 
were labeled with a goat anti-rabbit IgG Alexa fluor-
594-conjugated antibody for 30 min [66]. After a third 
washing, the cells were incubated with 0.1 μg/ml Hoechst 
33342 and mounted under a cover slip with glycerol. The 
cells were observed with an Olympus BX51 microscope.
In vivo treatment of BALB/c mice with GDC-0449 
or GANT-61
Groups of 6-to-8-week-old BALB/c female mice 
(5 mice per group) were subcutaneously inoculated in the 
right flank with 0.2 ml of suspension containing 1x106 
TUBO cells in phosphate-buffered saline (PBS) and 
treated per os with GDC-0449 (2 mg dissolved in 100 
µl of corn oil-ethanol in a 4:1 ratio, 3 times per week), 
GANT-61 (2 mg dissolved in 100 µl of corn oil-ethanol in 
a 4:1 ratio, 1 time per week) or corn oil-ethanol (100 µl in 
a 4:1 ratio, 3 times per week). The treatments were started 
simultaneously with the inoculation of TUBO cells.
Investigation has been conducted in accordance with 
the ethical standards and according to the Declaration of 
Helsinki. A veterinary surgeon was present during the 
experiments. The animal care both before and after the 
experiments was performed only by trained personnel. 
Mice were bred under pathogen-free conditions in the 
animal facilities of Tor Vergata University and handled 
in compliance with European Union and institutional 
standards for animal research.
Analysis of antitumor activity in vivo
Tumor growth was monitored weekly until tumor-
bearing mice were sacrificed at the first signs of distress or 
when their tumors exceeded 20 mm in diameter [67]. The 
tumors were measured with a caliper in two dimensions 
and the volumes were calculated by using the following 
formula: width2 x length/2 [68]. 
Statistical analysis
Differences in GLI1, Shh and NF-κB expression and 
their association with clinico-pathological parameters were 
evaluated using Fisher’s exact test and Student’s t-test. 
Values with p≤ 0.05 were considered significant. The data 
distribution of cell survival and the FACS analyses were 
preliminarily verified by Kolmogorov-Smirnov test, and 
data sets were analyzed by one-way analysis of variance 
(ANOVA) followed by Newman-Keuls test. Differences 
in GLI1 or Ptch mRNA expression levels and the intensity 
of immunoreactive bands were evaluated by a two-tailed 
Student’s t-test. Values with p≤ 0.05 were considered 
significant. Survival curves and tumor multiplicity were 
estimated by Kaplan-Meier method and compared by log-
rank test (Mantel-Cox). Differences in tumor volumes 
were regarded as significant when the p value was ≤ 0.05 
[66].
Abbreviations
HH/GLI, Hedgehog (Hh)/Glioma-associated 
oncogene (GLI); Shh, Sonic Hedgehog; Ptch, Patched-1; 
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